Drug Use Investigation for HEPSERA (Adefovir) Tablet
- Registration Number
- NCT01863589
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
This post-marketing surveillance (PMS) is conducted to collect safety and efficacy data among subjects with chronic hepatitis B and hepatic cirrhosis B who is treated with adefovir tablets.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 436
Inclusion Criteria
- Subjects with chronic hepatitis B or hepatic cirrhosis B
- Subjects treated with adefovir tablets
Exclusion Criteria
- None
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Subjects prescribed adefovir tablets Adefovir tablets Subjects with chronic hepatitis B or hepatic cirrhosis B to whom adefovir tablets are administered
- Primary Outcome Measures
Name Time Method The incidence of adverse drug reactions 1 year
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of adefovir in treating chronic hepatitis B and hepatic cirrhosis B?
How does adefovir compare to other nucleotide analogs in managing HBeAg-positive chronic hepatitis B patients?
Which biomarkers correlate with adefovir response in cirrhotic hepatitis B patients?
What are the long-term adverse events associated with adefovir therapy in post-marketing surveillance?
How effective is adefovir combination therapy versus monotherapy in hepatitis B treatment-resistant cases?